Abstract 341P
Background
Preclinical evidence using mouse model suggests that thermal/cold stress increases tumor growth by modulating the tumor microenvironment; however, the clinical relevance of temperature on BC outcomes is unknown. Studies show that residing in cold regions is associated with higher incidence of BC. We aim to study the impact of environmental temperature on the pathological complete response (pCR) and survival of early-stage BC patients (pts).
Methods
A multi-institutional study was conducted within the Oncology Research Information Exchange Network. We analyzed the clinical and genomic data for early-stage BC pts from 12 centers in the United States from different environment zones (5 warm (W) and 7 cold (C)) (based on average annual regional temperature obtained from National Centers for Environmental Information). Cox regression was used to measure the association of climate and overall/relapse-free survival (OS/RFS) after adjusting for confounders.
Results
Out of the 1,304 early-stage BC pts, 271 pts received neoadjuvant chemotherapy (NAC) (186 W, 85 C). Higher clinical T- and N-stages were observed in pts from W compared to C regions (p<0.001). Pts residing in C regions had more comorbidities (57.6% vs 48%, p<0.001). Pts in W regions had higher pCR, though not statistically significant (8% vs 2.5%, p= 0.1). The OS (univariate (UV) HR= 0.48, 95% CI 0.27-0.64, p <0.001; multivariate (MV) aHR= 0.56, 95% CI 0.32 - 0.96, p= 0.03) and RFS (UV HR= 0.51, 95% CI 0.38 - 0.68, p<0.001; MV aHR= 0.52, 95% CI 0.36 - 0.75, p= 0.0005) were higher in pts from W compared to C regions (Table). The OS (aHR= 0.35, p= 0.02) and RFS (aHR= 0.49, p= 0.02) of pts who received NACT were also higher in W regions. Table: 341P
Regions (n) | 5-yr OS (95% CI) | Median OS (months) (95% CI) | 5-yr RFS (95% CI) | Median RFS (95% CI) | p-value |
Cold (782) | 83 (76-86) % | 157.7 (116.6-NR) | 69 (62-76) % | 108.4 (88.9-147.8) | <0.001 |
Warm (522) | 95 (92-97) % | 214.7 (205.3-NR) | 83 (79-87) % | 250.4 (129.9-250.4) |
Conclusions
Early-stage BC pts living in cold have worse OS and RFS compared to warm regions. Larger studies are warranted to validate these interesting findings and further research focusing on therapeutic strategies to abrogate this outcome disparity by temperature is needed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
A.M. Roy.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
413P - Characteristics of patients (pts) with previously treated, oestrogen receptor-positive, HER2-negative advanced breast cancer (ER+, HER2– aBC) who had rapid progression (RP) in acelERA BC
Presenter: Miguel Martin Jimenez
Session: Poster session 03
414P - Trastuzumab deruxtecan for HER2-positive breast cancer brain metastasis: A systematic review and meta-analysis
Presenter: Isabella Michelon
Session: Poster session 03
415P - Patterns of time-to-progression intervals across clinical and liquid biopsy (LB) features in hormone receptor-positive (HR+) HER2-negative (HER2-) metastatic breast cancer (MBC) patients (pts) treated with first-line endocrine therapy (ET)
Presenter: Linda Cucciniello
Session: Poster session 03
416P - Cost-effectiveness of first-line (1L) ribociclib use vs palbociclib in the treatment of postmenopausal women with HR+/HER2− advanced breast cancer (ABC): Analysis based on final overall survival (OS) results of MONALEESA-2 (ML-2) and PALOMA-2 (PAL-2)
Presenter: Sandeep Sehdev
Session: Poster session 03
417P - New insights into second-line (2L) choices after CDK4/6 inhibitors (CDK4/6i) in hormone receptor-positive (HR+)/ human epidermal growth factor 2-negative (HER2-) metastatic breast cancer (MBC) patients (pts): Preliminary results of the HERMIONE-13 study
Presenter: Viola Cogliati
Session: Poster session 03
418P - Two-year follow-up data on the efficacy and safety of KN026, a HER2-targeted bispecific antibody combined with docetaxel as first-line treatment for HER2-positive recurrent/metastatic breast cancer
Presenter: Qingyuan Zhang
Session: Poster session 03
419P - Aspire to ASCENT: Real-world outcomes from patients with metastatic triple-negative breast cancer (mTNBC) treated with Sacituzumab govitecan (Saci) in a single academic institution
Presenter: Elaine Walsh
Session: Poster session 03
421P - Changes in cell-free DNA after short-term palbociclib and fulvestrant treatment for advanced or metastatic hormone receptor-positive and human epidermal growth factor 2-negative breast cancer
Presenter: Takayuki Iwamoto
Session: Poster session 03
422P - UK real-world data (RWD) of cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) use in metastatic breast cancer (MBC)
Presenter: Georgina Gullick
Session: Poster session 03
423P - A real-world study on the clinical value of apatinib-based regimens in metastatic triple-negative breast cancer
Presenter: Huang wei
Session: Poster session 03